IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 董事名單及其角色與職能 華 檢 醫 療 控 股 有 限 公 司 董 事 會（「董事會」）成 員 載 列 如 下： | 林賢雅 | | 執行董事兼總經理 | | --- | --- | --- | | 陳兆基 | | 執行董事 | | 羅劍輝 | | 執行董事兼首席財務官 | | 姚海雲 | | 非執行董事 | | 劉 | 飛 | 非執行董事 | | 仲人前 | | 獨立非執行董事 | | 黃思樂 | | 獨立非執行董事 | | 邰 | 洋 | 獨立非執行董事 | | 徐 | 達 | 獨立非執行董事 | | 張建磊 | | 獨立非執行董事 | 下 表 載 列 各 董 事 會 成 員 任 職 於 以 下 三 個 董 事 會 委 員 會 的 成 員 資 料。 | | 委員會 | 審 | 計 | 薪 | 酬 | 提 | 名 | | --- | --- | --- | --- | --- | --- | --- | --- | | 董 事 | | | 委員會 | | 委員會 | | 委 ...

Group 1 - The company reported a revenue of RMB 1.27 billion for the first half of 2025, with distribution business revenue accounting for RMB 1.177 billion, representing 92.7% of total revenue [1] - The company has established a large distribution network covering 31 provinces, municipalities, and autonomous regions in China, with 236 direct clients and 1,073 distributors as of June 30, 2025 [1] - The company aims to leverage the high growth potential of the IVD market by diversifying product categories, expanding brand coverage, and enhancing its distribution network and hospital reach [1] Group 2 - The company has entered into a global strategic cooperation framework agreement with HashKey Group, marking a significant milestone in the integration of blockchain finance and medical innovation [2] - This collaboration will utilize HashKey's compliant trading platform and global liquidity network to assist the company in executing large-scale Ethereum (ETH) transactions and optimizing over-the-counter trading costs [2] - The partnership aims to quickly establish and expand a "Global Enhanced Ethereum Vault," improving capital efficiency and providing reliable support for future tokenization research and development projects [2]

格隆汇8月29日丨华检医疗(01931.HK)公告，梁嘉声博士已告知公司董事会其退休计划。彼将退任独立 非执行董事，自2025年9月1日起生效。彼亦将自同日起不再担任公司审计委员会、薪酬委员会及提名委 员会成员。 ...

Core Viewpoint - Huajian Medical (01931) reported a revenue of 1.27 billion and a profit attributable to shareholders of 39.12 million for the six months ending June 30, 2025, with an adjusted profit of 35.63 million and earnings per share of 2.41 cents [1] Group 1: Financial Performance - The company achieved a revenue of 1.27 billion [1] - Profit attributable to shareholders was 39.12 million [1] - Adjusted profit stood at 35.63 million [1] - Earnings per share were reported at 2.41 cents [1] Group 2: Strategic Outlook - The company aims to consolidate its core IVD business while exploring the strategic value of robotics and cutting-edge technologies [1] - The focus is on leveraging insights into technological innovation and market demand within the medical industry [1] - The company plans to utilize capital markets to strengthen its leading position in China's IVD industry and adopt proactive development strategies [1]

Group 1 - The company reported a revenue of 1.27 billion and a profit attributable to shareholders of 39.12 million for the six months ending June 30, 2025 [1] - Adjusted profit was 35.63 million, with earnings per share at 2.41 cents [1] - The company aims to expand its technological innovation boundaries while consolidating its core IVD business, focusing on robotics and cutting-edge technologies to seize growth opportunities from global technological changes [1] Group 2 - The company plans to leverage capital markets to strengthen its leading position in China's IVD industry and adopt proactive development strategies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 華 檢 醫 療 控 股 有 限 公 司（「本公司」）宣 佈，梁 嘉 聲 博 士 已 告 知 本 公 司 董 事（「董 事」） 會（「董事會」）其 退 休 計 劃。彼 將 退 任 獨 立 非 執 行 董 事，自 二 零 二 五 年 九 月 一 日 起 生 效。彼 亦 將 自 同 日 起 不 再 擔 任 本 公 司 審 計 委 員 會、薪 酬 委 員 會 及 提 名 委 員 會 成 員。 梁 博 士 已 確 認 其 與 董 事 會 並 無 意 見 分 歧，亦 無 任 何 與 其 退 任 相 關 事 宜 需 提 呈 本 公 司 股 東 垂 注，或 根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」） 第13.51(2)條 予 以 披 露。 本 公 司 感 謝 梁 博 士 對 本 集 團 的 領 導 及 貢 獻。 委任 ...

華 檢 醫 療 控 股 有 限 公 司（「本公司」）董 事（「董 事」，各 自 為「董 事」）會（「董事會」） 謹 此 宣 佈 本 公 司 及 其 附 屬 公 司（此 後 統 稱「本集團」）截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月（「報告期間」）的 未 經 審 核 綜 合 中 期 業 績，其 已 經 本 公 司 審 核 委 員 會（「審核委員會」）審 閱 及 已 經 董 事 會 於 二 零 二 五 年 八 月 二 十 九 日 核 准。本 集 團 於 報 告 期 間 的 財 務 摘 要 連 同 二 零 二 四 年 同 期 的 比 較 數 字 載 列 如 下： 截至六月三十日止六個月 | | | | | | | | | | | | 二零二五年 | | 二零二四年 | | 變 動 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | | 人民幣千元 | | 人民幣千元 | | | | | | | | | | ...

Core Viewpoint - 华检医疗's stock price increased by over 16%, reaching 9.64 HKD, with a trading volume of 29.15 million HKD, following the announcement of a board meeting scheduled for August 29, 2025, to discuss mid-term performance and potential dividend payments [1] Group 1 - The company has launched several key strategic initiatives since late July, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [1] - The company is pushing its U.S. subsidiary to apply for a stablecoin license and has partnered with BGI's subsidiary to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [1] - On August 8, the company announced the launch of a "Global Enhanced Ethereum (ETH) Treasury" strategy and completed the compliant purchase of 149 million HKD in ETH in collaboration with licensed exchange HashKey [1] Group 2 - The company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the medical innovative drug RWA trading platform ecosystem [1]

Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, rising over 16% in the afternoon trading session, attributed to strategic initiatives and upcoming financial announcements [1] Group 1: Stock Performance - As of the latest update, Huajian Medical's stock price is reported at 9.64 HKD, with a trading volume of 29.1585 million HKD [1] Group 2: Strategic Initiatives - The company announced a board meeting scheduled for August 29, 2025, to consider and approve the mid-term performance for the six months ending June 30, 2025, and to discuss potential interim dividends [1] - Since late July, Huajian Medical has launched several key strategic initiatives, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [1] - The company is pushing its U.S. subsidiary to apply for a stablecoin license and has partnered with BGI's subsidiary to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [1] - On August 8, Huajian Medical officially launched the "Global Enhanced Ethereum (ETH) Treasury" strategy, collaborating with the licensed exchange HashKey and completing a compliant purchase of 149 million HKD in ETH [1] - Recently, the company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the medical innovation drug RWA trading platform [1]

Core Insights - The establishment of the "Hong Kong Digital Asset Listed Companies Association" marks a significant step in promoting digital assets in Hong Kong, with participation from over 80 listed companies and financial institutions [1][2] - The Hong Kong government is committed to fostering innovation in financial technology, with over 1,100 fintech companies operating in the region and a 15% annual growth rate [1][2] Group 1: Government Initiatives - The Hong Kong government plans to regularize the issuance of green bonds and explore tokenization applications in various sectors, including renewable energy [2] - A funding program has been launched to support projects with commercial potential, offering up to HKD 500,000 for tokenization certification and commercialization [2] Group 2: Participating Companies - A list of participating companies includes notable H-shares such as Guofu Quantum, China New Economy Investment, and Huya Capital, among others [3] - A-share participants include Zhaoxin Co. and Jingbeifang, while US-listed companies include Galaxy Digital and Amber [4]